Promius Pharma, a wholly-owned subsidiary of Hyderabad-based pharmaceutical major Dr Reddy's Laboratories (DRL), has entered a collaborative agreement with US-based Valeant Pharmaceuticals International, to market Cloderm cream in the US market.
Under the agreement, Promius Pharma would make an upfront payment and would pay future royalties for the rights to manufacture, distribute and market the drug in US. However, the financial terms and conditions of the agreement are not disclosed.
Raghav Chari, senior vice-president and head (proprientary products), Promius Pharma said, “The addition of Cloderm cream, which is used to treat dermatological inflammation, will bolster our ongoing efforts to build a strong commercial and clinical presence in US through branded franchise.”